Drug-coated balloons (DCB) for symptomatic intracranial atherosclerotic stenosis: a systematic review and meta-analysis.

Authors

Chien-Hung Chang, Ching-Chang Chen, Chun-Ting Chen, Mun-Chun Yeap, Shuo-Chi Chien, Yi-Ming Wu, Zhuo-Hao Liu

Published in

Cardiovascular diagnosis and therapy. Volume 16. Issue 3. Pages 45. Jun 18, 2026. Epub Jun 15, 2026.

Abstract

Intracranial atherosclerosis is a major cause of ischemic stroke, with high restenosis rates following angioplasty and stenting. Drug-coated balloons (DCBs) offer a potential alternative by delivering antiproliferative drugs to reduce restenosis. This systematic review and meta-analysis aimed to evaluate the restenosis rate and effectiveness of DCBs in treating intracranial atherosclerosis.
PubMed, EMBASE, and Cochrane CENTRAL were searched from inception to April 13, 2025 (date of search). Eligible studies included randomized trials, and prospective and retrospective cohort studies evaluating DCBs in patients with symptomatic intracranial atherosclerosis. The primary outcomes were restenosis rate and degree of stenosis post-DCB treatment. Pooled proportions and odds ratios (ORs) with 95% confidence interval (CI) were calculated. Heterogeneity was assessed using the I² statistic, and risk of bias with the Newcastle-Ottawa Scale.
Twenty-six studies involving 1,489 patients were included. The pooled restenosis rate after DCB treatment was 11% (95% CI: 9-13%; I²=26.8%). The pooled mean degree of stenosis after treatment was 34.34% (95% CI: 29.85-38.84%; I²=93.9%). In comparative studies, DCB was associated with a significantly lower restenosis rate than non-DCB treatment (OR =0.26; 95% CI: 0.16-0.44; P<0.001; I²=0%). No significant difference was observed in post-treatment stenosis between groups (mean difference =14.58; 95% CI: -5.98 to 35.14; P=0.17; I²=92.5%).
Restenosis rates following DCB treatment appear low and may be lower than those observed with non-DCB treatments in comparative studies. However, given the substantial heterogeneity in stenosis-related outcomes and the predominance of retrospective cohort studies, these findings should be interpreted cautiously. High-quality prospective studies, ideally randomized controlled trials, are warranted to better establish the long-term efficacy of DCB treatment.

PMID:
42428645
Bibliographic data and abstract were imported from PubMed on 10 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.